Interoperability: biolog-id Technology Soon to Be Available From Inlog Software
6.7.2021 18:03:00 EEST | Business Wire | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Inlog, a software company dedicated to the medical sector, have announced today a strategic interoperability partnership for their solutions.
With a market presence of more than 30 years, Inlog has developed software suites that ensure the quality and the traceability of products throughout the transfusion supply chain. These software suites are used today by nearly 250 French and international clients, including an important part of University Hospitals.
To allow blood centers and hospitals to take advantage of the RFID technology, Inlog and biolog-id are partnering to guarantee the interoperability of the Edge Track (Hemo Server) and Edge Blood (CTS Server) software with the Biolog Data System modules from the Biolog Transfusion Solution.
By combining RFID tags containing essential information of blood products, connected equipment, and a dedicated transactional and decision-making software, Biolog Transfusion Solution secures the entire blood transfusion supply chain, from the donor to the recipient. Beyond reinforcing the safety of transfused patients, the solution optimizes in real-time the local and remote inventory management of these vital therapeutic products and allows them to be attributed nominatively remotely and safely.
“We are very pleased that Inlog, who is today a reference in the field of blood supply chain management, and biolog-id collaborate to propose their users and prospects an option for strengthening traceability and securing the transfusion chain based on our RFID solution”, says Bruno Chappert, CEO at biolog-id. “This interoperability agreement will enable us to offer transfusion professionals a new feature capable of improving their efficiency, optimizing working conditions while adapting to all types of structures, and finally facilitating the rapid implementation of these software solutions”.
“We are convinced that this interoperability agreement between biolog-id and Inlog will provide healthcare and transfusion facilities with better blood product management, enhanced safety and improved traceability”, underlines David Kalfon, President at Inlog. “The numerous combined advantages of biolog-id and Inlog solutions will allow the transfusion chain professionals to rationalize their operations and optimize their costs”.
The Inlog software and Biolog Transfusion Solution will be available under different technical models to allow simple, fast and modular integration by healthcare infrastructures and to meet users’ needs.
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Inlog:
Founded in 1992, Inlog is one of the leading French software companies in the field of medical informatics for laboratory analysis, traceability of blood products in healthcare facilities and the various activities of blood transfusion centers.
Inlog designs and develops a range of software for the healthcare sector whose advantages in terms of robustness, reliability and ease of configuration are distinguished by all its customers. Motivated by a new management board, Inlog is initiating an ambitious project to use new technologies into its applications to make their use even more ergonomic and intuitive.
The Inlog software suites, CE marked, are used by more than 250 Healthcare institutions in France and around the world (Germany, Switzerland, Belgium, Canada, Hong Kong, etc.), including some prestigious partners such as the Etablissement Français du Sang, the Hôpitaux Universitaires Genevois and the Flemish Red Cross.
Inlog is currently supported by the French investment fund Abénex, a major player in private equity in France.
Company URL: https://www.inlog.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005565/en/
Contact information
biolog-id
Astrid Billard, astrid.billard@biolog-id.com
Inlog
David Delay,
david.delay@inlog.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leaders of Dubai-Based Unicorns Hail City as Global Innovation Hub Shaping Future Technology and Driving the Digital Economy20.4.2026 16:08:00 EEST | Press release
Leaders of Dubai-based unicorn companies have reaffirmed the emirate’s status as a global hub for digital innovation and technology-led growth. The senior executives highlighted Dubai’s forward-looking regulatory environment, advanced infrastructure, and ability to attract international talent as key factors strengthening its appeal for high-growth digital businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420503062/en/ Leaders of Dubai-based unicorns hail city as global innovation hub shaping future technology and driving the digital economy (Photo: AETOSWire) They noted that Dubai has evolved into a strategic launchpad for ambitious companies, offering an agile business environment that supports innovation and enables expansion into regional and international markets. The business leaders also praised the strong alignment between the public and private sectors within Dubai’s digital ecosystem, supported by Dubai
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Capcom’s All-New IP PRAGMATA Surpasses One Million Units Sold in Two Days!20.4.2026 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of PRAGMATA, the company’s all-new IP released on April 17, 2026*, have surpassed one million units. PRAGMATA is a science-fiction action-adventure game that depicts the journey of Hugh Williams and Diana, an android girl, in a near-future lunar world. A completely new IP, PRAGMATA was developed primarily by a team of younger Capcom developers, who created an innovative gameplay experience by fusing action gameplay with puzzle elements set within a distinctive world ruled over by artificial intelligence. In the absence of an established fan base or preexisting brand recognition, Capcom implemented a range of marketing initiatives—beginning with the early release of a playable demo—to communicate the unique features of the game to a wider audience. In addition, in line with the company’s multi-platform strategy, Capcom broadened the title’s availability by adding support for Nintendo Switch™ 2 at an early stage. As a res
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 15:30:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom